Gastrointestinal Cancer

The XELAVIRI trial failed to demonstrate the noninferiority of a sequential escalation treatment strategy vs initial combination therapy in mCRC.

A study takes a closer look at colorectal cancer screening incentives among New York State Medicaid managed care patients.

A study looks at how dietary patterns impact colorectal cancer outcomes before and after diagnosis.

A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC.

Dr. Luis Diaz spoke with Cancer Network about monitoring for residual disease in colon cancer ahead of his presentation at ESMO 2018.

Until recent studies were reported, immunotherapy was thought to be ineffective for colorectal cancer; this article provides guidance on how to incorporate immunotherapy into this setting.

Radioguided surgery using gallium 68 dota peptides offers a highly sensitive method for detecting neuroendocrine tumors.

A study of an equal-access military health system shows universal health insurance for both the military and civilian populations could improve CRC screening rates.

A study shows ZEB2 has clinical potential and may improve TNM risk-stratification and guide treatment in colorectal cancer.

In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.

A study finds tailored phone intervention significantly increases colorectal cancer screening compared to usual care.

The survival advantages associated with NCCN guideline–driven care were not realized in younger patients with stage II and stage III rectal cancer.

In an interview with Cancer Network, Lorraine Drapek describes a multidisciplinary program at MGH to support vaginal and sexual health post RT for GI and gynecologic malignancies.

Canadian Cancer Trials Group investigators say it's unclear if disease biology is different in younger patients or if older ones are more likely to undergo screening.

Early‐onset rectal cancer may differ biologically and in its response to multimodality therapy, according to a large retrospective study of NCCN data.

Combination therapy with a high-dose proton pump inhibitor and aspirin reduced the risk of progression to esophageal cancer in patients with Barrett esophagus.

MSKCC’s Dr. Nancy Kemeny discusses the impact of a company's decision to halt manufacture of a pump used to treat liver mets from colon and rectal cancers.

In this Q&A, we discuss the research into the relationships between gut microbiota, diet, and colorectal cancer.

Researchers from MD Anderson say their study results "open the field of immunoprevention in LS to checkpoint inhibitors as an immune interception strategy."

In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.

In this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.

Previous studies found calcium channel blockers could prevent pancreatic cancer, but have neglected to consider the effects of short-acting CCBs.

A highly selective small molecule A3AR agonist blocked development of oxaliplatin-induced neuropathic pain without interfering with anticancer effects.

A team of Finnish researchers has created a deep learning algorithm that appears to help clinicians better predict patient outcomes based on colorectal cancer tissue samples.

The STAT3 inhibitor napabucasin significantly improved survival among patients with colorectal cancer with elevated phosphorylated STAT3 expression.